{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021534","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.855012+00:00","generated_at":"2026-06-22T10:55:51.945098+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Orthofix Q3: net sales $114M, GAAP EPS ($0.53); FY22 adj. EBITDA guidance cut; SeaSpine merger","bullets":["Net sales $114.0M, up 1% reported, 5% constant currency; Global Orthopedics grew 19% constant currency.","GAAP EPS ($0.53) vs ($0.11) prior year; adjusted EPS $0.13 vs $0.10.","Net loss widened to $10.7M from $2.2M; adjusted net income $2.7M.","FY2022 guidance lowered: net sales $457-463M, adjusted EBITDA $52-54M (from $53-57M), adjusted EPS $0.40-0.50 (from $0.45-0.55).","Announced agreement to merge with SeaSpine in all-stock merger of equals on October 11, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021534","json":"https://secwatch.observer/filing/0000950170-22-021534.json","markdown":"https://secwatch.observer/filing/0000950170-22-021534.md","text":"https://secwatch.observer/filing/0000950170-22-021534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017022021534/0000950170-22-021534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017022021534/ofix-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:55:51.945098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed12dd4def909253b10ccb085cf36087e244fb89","claim":"Orthofix Medical Inc. reported third quarter ended September 30, 2022 results: revenue $114.0 million, net income Net loss was $(10.7) million, EPS $(0.53) per share. Guidance reaffirmed.","evidence_excerpt":"Orthofix Reports Third Quarter 2022 Results • Net sales of $114.0 million, an increase of 1% on a reported basis and 5% on a constant currency basis over prior year • Global Orthopedics net sales growth of 19% on a constant currency basis driven by new product and channel investments • GAAP EPS of ($0.53) and adjusted EPS of $0.13","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017022021534/0000950170-22-021534-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$114.0 million"},{"label":"Net income","value":"Net loss was $(10.7) million"},{"label":"EPS","value":"$(0.53) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}